These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4600763)

  • 1. Biochemical and physiological properties of carbamylated hemoglobin S.
    Manning JM; Cerami A; Gillette PN; De Furia FG; Miller DR
    Adv Enzymol Relat Areas Mol Biol; 1974; 40(0):1-27. PubMed ID: 4600763
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between the oxygen affinity and in vitro sickling propensity of carbamylated sickle erythrocytes.
    Diederich D
    Biochem Biophys Res Commun; 1972 Feb; 46(3):1255-61. PubMed ID: 5012168
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of hemoglobin carbamylation on the survival of human sickle cell erythrocytes in rats.
    Castro O; Orlin J; Finch SC
    Yale J Biol Med; 1974 Mar; 47(1):55-60. PubMed ID: 4825087
    [No Abstract]   [Full Text] [Related]  

  • 4. Kinetics of the carbamylation of the amino groups of sickle cell hemoglobin by cyanate.
    Lee CK; Manning JM
    J Biol Chem; 1973 Aug; 248(16):5861-5. PubMed ID: 4723918
    [No Abstract]   [Full Text] [Related]  

  • 5. Deoxyhemoglobin S: solubility vs. erythrocyte sickling.
    Vedvick TS; Koenig HM; Itano HA
    Clin Biochem; 1975 Aug; 8(4):288-90. PubMed ID: 1157297
    [No Abstract]   [Full Text] [Related]  

  • 6. Solubility changes observed in sickle cell hemoglobin as the amino groups are carbamylated.
    Vedvick TS; Koenig HM; Itano HA
    Proc Soc Exp Biol Med; 1974 Oct; 147(1):255-8. PubMed ID: 4438331
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of sickle hemoglobin and desickling agents by falling ball viscometry.
    Paniker NV; Ben-Bassat I; Beutler E
    J Lab Clin Med; 1972 Aug; 80(2):282-90. PubMed ID: 4339821
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of the development of cyanate as a drug in the treatment of sickle cell anemia.
    Cerami A
    Ann N Y Acad Sci; 1974 Nov; 241(0):538-44. PubMed ID: 4611307
    [No Abstract]   [Full Text] [Related]  

  • 9. Some comparative aspects of carbamylation of human blood and of hemoglobin with cyanate and carbamyl phosphate.
    Carreras-Barnes J; Diederich DA; Grisolia S
    Eur J Biochem; 1972 May; 27(1):103-8. PubMed ID: 5049047
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on the mechanism of action of cyanate in sickle cell disease. Oxygen affinity and gelling properties of hemoglobin S carbamylated on specific chains.
    Nigen AM; Njikam N; Lee CK; Manning JM
    J Biol Chem; 1974 Oct; 249(20):6611-6. PubMed ID: 4421180
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemical and biological aspects of the inhibition of red blood cell sickling by cyanate.
    Manning JM; Cerami A; Gillette PN; De Furia FG; Miller DR
    Adv Exp Med Biol; 1972; 28():253-60. PubMed ID: 5085171
    [No Abstract]   [Full Text] [Related]  

  • 12. The interactions of sickle hemoglobin.
    Ranney HM
    Biochimie; 1972; 54(5):633-8. PubMed ID: 4654160
    [No Abstract]   [Full Text] [Related]  

  • 13. Cyanate and sickle-cell disease.
    Cerami A; Peterson CM
    Sci Am; 1975 Apr; 232(4):44-50. PubMed ID: 1114310
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanism of sickling in deer erythrocytes.
    Amma EL; Sproul GD; Wong S; Huisman TH
    Ann N Y Acad Sci; 1974 Nov; 241(0):605-13. PubMed ID: 4530684
    [No Abstract]   [Full Text] [Related]  

  • 15. Carbamylation of the chains of hemoglobin S by cyanate in vitro and in vivo.
    Njikam N; Jones WM; Nigen AM; Gillette PN; Williams RC; Manning JM
    J Biol Chem; 1973 Dec; 248(23):8052-6. PubMed ID: 4752945
    [No Abstract]   [Full Text] [Related]  

  • 16. Carbamyl phosphate modification of hemoglobin S structure resulting in altered sickling.
    Kraus LM; Rasad A; Kraus AP
    Adv Exp Med Biol; 1972; 28():279-96. PubMed ID: 5085172
    [No Abstract]   [Full Text] [Related]  

  • 17. Hematologic and clinical responses in patients with sickle cell anemia after chronic extracorporeal red cell carbamylation.
    Deiderich DA; Trueworthy RC; Gill P; Cader AM; Larsen WE
    J Clin Invest; 1976 Sep; 58(3):642-53. PubMed ID: 956392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of cyanate in vitro on red blood cell metabolism and function in sickle cell anemia.
    De Furia FG; Miller DR; Cerami A; Manning JM
    J Clin Invest; 1972 Mar; 51(3):566-74. PubMed ID: 5011101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of cyanate with a summary of its initial usage in sickle cell disease.
    Gillette PN; Lu YS; Peterson CM
    Prog Hematol; 1973; 8():181-90. PubMed ID: 4788375
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of urea and cyanate on sickling in vitro.
    Segel GB; Feig SA; Mentzer WC; McCaffrey RP; Wells R; Bunn HF; Shohet SB; Nathan DG
    N Engl J Med; 1972 Jul; 287(2):59-64. PubMed ID: 5031386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.